164 related articles for article (PubMed ID: 38085895)
21. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents.
Ferreri AJM
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):565-577. PubMed ID: 29222306
[TBL] [Abstract][Full Text] [Related]
22. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
23. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
Wight JC; Yue M; Keane C; Johnston A; Linton K; Chin C; Wai SH; Talaulikar D; Gasiorowski R; Cheah CY; Gregory GP; Dickinson M; Minson A; Coombes C; Ku M; Lam S; Hawkes EA
Br J Haematol; 2019 Oct; 187(2):174-184. PubMed ID: 31236941
[TBL] [Abstract][Full Text] [Related]
25. Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.
Holdhoff M; Mrugala MM; Grommes C; Kaley TJ; Swinnen LJ; Perez-Heydrich C; Nayak L
J Natl Compr Canc Netw; 2020 Nov; 18(11):1571-1578. PubMed ID: 33152700
[TBL] [Abstract][Full Text] [Related]
26. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas.
Zing N; Fischer T; Federico M; Chiattone C; Ferreri AJM
Crit Rev Oncol Hematol; 2021 Nov; 167():103496. PubMed ID: 34653598
[TBL] [Abstract][Full Text] [Related]
28. Primary Central Nervous System Lymphomas.
Chukwueke U; Grommes C; Nayak L
Hematol Oncol Clin North Am; 2022 Feb; 36(1):147-159. PubMed ID: 34801161
[TBL] [Abstract][Full Text] [Related]
29. [New treatment strategies for primary lymphoma of the central nervous system].
Seidel S; Kaulen L; von Baumgarten L
Nervenarzt; 2024 Feb; 95(2):117-124. PubMed ID: 37910181
[TBL] [Abstract][Full Text] [Related]
30. Advances in Primary Central Nervous System Lymphoma.
Patrick LB; Mohile NA
Curr Oncol Rep; 2015 Dec; 17(12):60. PubMed ID: 26475775
[TBL] [Abstract][Full Text] [Related]
31. Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
Zhang N; Xu D; Liu B; Shi X; Xie X; Wang Z
Int Immunopharmacol; 2022 Dec; 113(Pt A):109299. PubMed ID: 36252471
[TBL] [Abstract][Full Text] [Related]
32. Challenges in the management of primary central nervous system lymphoma.
Sun X; Lv L; Wu Y; Cui Q; Sun S; Ji N; Liu Y
Crit Rev Oncol Hematol; 2023 Aug; 188():104042. PubMed ID: 37277008
[TBL] [Abstract][Full Text] [Related]
33. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment.
van Besien K; Gisselbrecht C; Pfreundschuh M; Zucca E
Leuk Lymphoma; 2008; 49 Suppl 1():52-8. PubMed ID: 18821433
[TBL] [Abstract][Full Text] [Related]
34. Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer/T-cell lymphoma.
Nevel KS; Pentsova E; Daras M
Leuk Lymphoma; 2019 Jul; 60(7):1677-1684. PubMed ID: 30648449
[TBL] [Abstract][Full Text] [Related]
35. Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma.
Bobillo S; Wilson MR; Cwynarski K
Curr Opin Oncol; 2023 Sep; 35(5):382-388. PubMed ID: 37551947
[TBL] [Abstract][Full Text] [Related]
36. Updates on Primary Central Nervous System Lymphoma.
Schaff LR; Grommes C
Curr Oncol Rep; 2018 Feb; 20(2):11. PubMed ID: 29492682
[TBL] [Abstract][Full Text] [Related]
37. Management of primary and secondary CNS lymphoma.
Khwaja J; Cwynarski K
Hematol Oncol; 2023 Jun; 41 Suppl 1():25-35. PubMed ID: 37294958
[TBL] [Abstract][Full Text] [Related]
38. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
39. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
[TBL] [Abstract][Full Text] [Related]
40. The Diagnosis and Treatment of Primary CNS Lymphoma.
von Baumgarten L; Illerhaus G; Korfel A; Schlegel U; Deckert M; Dreyling M
Dtsch Arztebl Int; 2018 Jun; 115(25):419-426. PubMed ID: 29999484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
